Indivior Announces Completion of Redomiciliation to the United States
Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), today announced completion of its redomiciliation from the United Kingdom to the United States.
Read moreIndivior Pharmaceuticals, Inc. (Nasdaq: INDV), today announced completion of its redomiciliation from the United Kingdom to the United States.
Read moreIndivior PLC (Nasdaq: INDV) today announced the Company has concluded the legacy U.S. Department of Justice (DOJ) matter by paying in full the outstanding obligation of $295 million associated with the matter.
Read moreIndivior PLC (Nasdaq: INDV) (“Indivior PLC” or the “Company”) today announced that it will be added to the S&P SmallCap 600® index, effective today.
Read moreBoth monthly maintenance doses (100 mg and 300 mg) improved opioid abstinence and were well-tolerated with no new safety signals identified.
Read moreIndivior PLC (Nasdaq: INDV) today announced the Company has concluded the legacy U.S. Department of Justice (DOJ) matter by paying in full the outstanding obligation of $295 million associated with the matter.
Read moreIndivior PLC announced that it will participate in the Piper Sandler 37th Annual Healthcare Conference
Read moreIndivior PLC (Nasdaq: INDV) presented three new scientific posters at the Academy of Managed Care Pharmacy (AMCP) Nexus 2025 conference last week, showcasing real-world evidence on the clinical and economic impact of monthly injectable buprenorphine in the treatment of OUD.
Read moreIndivior Reports Third Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance
Read moreIndivior to Participate in the Stifel 2025 Healthcare Conference
Read more